摘要
目的 探讨老年冠心病患者使用低分子肝素的安全性。方法 观察 2 4例老年冠心病成功进行 PTCA术后及 51例对照组使用低分子肝素 (速避凝 ) 1 0 0 0 0 ICUAXa,每日 2次共 1 0 d后出血情况及凝血机制改变。结果 用药后两组出血情况、其它脏器合并症及凝血时间测定等均无明显差异 ,老年组血浆纤维蛋白原 (FBI)较对照组明显增高 (4.69± 1 .36,3.95± 1 .0 1 ,P<0 .0 5) ,对照组治疗后 FBI较治疗前明显降低 (3.95±1 .0 1 ,3.33± 0 .41 ,P<0 .0 5)。
? Objective In order to find the security of low molecular weight heparin used in elderly patients with coronary heart disease(CHD) Methods We observed the bleeding and blood coagubility(PLT,PT and APTT) in 24 elderly patients with CHD who were performed percutaneous transluminal coronary angioplasty and 51 young man controls with CHD,after hypodermical injection of low molecular weight heparin 10 000 ICUAXa twice a day for 10 days. Results There was no significant difference between the elderly and the controls in bleeding,complication.PLT,PT and APTT FIB was higher in the elderly patients than in the young controls(4 69±1 36 vs 3 95±1 01, P <0 05).FIB decreased apparently(3 95±1 01 vs 3 33±0 41, P <0 05)in the young controls after treatment.Conclusions These data suggest that elderly patients may have more serious coagulation.It is secure that elderly patients use low molecular weight heparin. 〔
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2001年第2期99-100,共2页
Chinese Journal of Gerontology
关键词
低分子肝素
冠心病
凝血机制
Low molecular weight heparin
Coagulation
CHD
